St. Louis Arch Angels-Backed Sequoia Sciences To Start Vaccine Clinical Trials

St. Louis-based Sequoia Sciences is preparing to start phase 1 of clinical trials for a vaccine that treats and prevents recurrent urinary tract infections. The St. Louis Arch Angels Network invested $6.6 million in the drug discovery company.

• 0
• 825 views

By Techli